Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial.
Yu FangNing SuQihua ZouYi CaoYi XiaLinquan TangXiaopeng TianPanpan LiuQing-Qing CaiPublished in: BMC medicine (2023)
ClinicalTrials.gov: NCT03906058.